IMV News and Press, IMV Inc. From 12/20/21

This facility supports the advancement of IMV’s lead candidate, maveropepimut-S (MVP-S) across a range of cancer indications, and the development of new DPX-based immunotherapies against cancer IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a po...

Translational data show that treatment with maveropepimut-S (MVP-S, previously known as DPX-Survivac) induces a sustained and effective anti-tumor immune response that involves both T and B cells IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfol...

IMV (NASDAQ:IMV) said the first patient with hormone receptor positive/HER2-negative (HR+/HER2-) breast cancer was dosed with its lead compound maveropepimut-S ((MVP-S, formerly known as DPX-Survivac)). In the phase 1b trial, MVP-S is being administered in combination with an aromatase inhibi...

For the first time, maveropepimut-S is being evaluated in a neoadjuvant combination and in patients with breast cancer Primary results of the study are expected in 2023 IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educat...

IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating cancer therapies based on its novel DPX platform, today announced that IMV’s executive management team will be participating ...

Pierre Labbé, the Chief Financial Officer of IMV (NASDAQ:IMV), will retire on March 31, 2022. An executive search firm has been hired to find a replacement. Labbé will continue to consult with IMV to support the transition after his retirement. Previously (Nov. 11): IMV EPS mis...

IMV Inc. (NASDAQ: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating cancer therapies based on its novel DPX platform, today announced that Pierre Labbé, the Company’s Chief Financial Offic...

The following slide deck was published by IMV Inc. in conjunction with their 2021 Q3 earnings call. For further details see: IMV Inc. 2021 Q3 - Results - Earnings Call Presentation

IMV Inc. (IMV) Q3 2021 Earnings Conference Call November 11, 2021, 08:00 AM ET Company Participants Joy Bessenger - SVP, IR and Corporate Strategy Pierre Labbe - CFO Andrew Hall - Interim CEO Jeremy Graff - Chief Scientific Officer Conference Call Participants Brandon Folkes - Cantor Fitzgera...

IMV (NASDAQ:IMV): Q3 GAAP EPS of -$0.13 misses by $0.01. Revenue of $0.04M (-55.6% Y/Y) misses by $0.02M. Press Release For further details see: IMV EPS misses by $0.01, misses on revenue